title: Hypotensive Effect and Accumulation of Dinitrosyl Iron Complexes in Blood and Tissues after Intravenous and Subcutaneous Injection.
abstract: Subcutaneous injection of Oxacom with glutathione-bound dinitrosyl iron complex as the active principle produced a slower drop of mean BP and longer accumulation of protein-bound dinitrosyl iron complexes in whole blood and tissues than intravenous injection of this drug, while durations of hypotensive effect in both cases were practically identical. In contrast to intravenous injection of the drug, its subcutaneous administration was not characterized by a high concentration of protein-bound dinitrosyl iron complexes in the blood at the onset of experiment; in addition, accumulation of these NO forms in the lungs was more pronounced after subcutaneous injection than after intravenous one.
authors.affiliation: Research Institute of Experimental Cardiology of Russian Cardiology Research and Production Complex, Ministry of Health of the Russian Federation, Moscow, Russia.
authors.forename: A A
authors.initials: AA
authors.lastname: Timoshin
authors.affiliation: Research Institute of Experimental Cardiology of Russian Cardiology Research and Production Complex, Ministry of Health of the Russian Federation, Moscow, Russia.
authors.forename: V L
authors.initials: VL
authors.lastname: Lakomkin
authors.affiliation: Research Institute of Experimental Cardiology of Russian Cardiology Research and Production Complex, Ministry of Health of the Russian Federation, Moscow, Russia.
authors.forename: A A
authors.initials: AA
authors.lastname: Abramov
authors.affiliation: Research Institute of Experimental Cardiology of Russian Cardiology Research and Production Complex, Ministry of Health of the Russian Federation, Moscow, Russia.
authors.forename: E K
authors.initials: EK
authors.lastname: Ruuge
authors.affiliation: N. N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow, Russia.
authors.forename: A F
authors.initials: AF
authors.lastname: Vanin
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D001711:Biotransformation; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007501:Iron / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008168:Lung / Q000378:metabolism; D008297:Male; D018482:Muscle, Skeletal / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D009569:Nitric Oxide / Q000097:blood*; D020030:Nitric Oxide Donors / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D009589:Nitrogen Oxides / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000959:Antihypertensive Agents; D020030:Nitric Oxide Donors; D009589:Nitrogen Oxides; D009569:Nitric Oxide; C073661:dinitrosyl iron complex; D007501:Iron
keywords: NO donor; dinitrosyl iron complexes; electron paramagnetic resonance; hypotensive effect; nitric oxide